Introduction {#S1}
============

Laryngeal squamocellular carcinoma (LSCC) accounts for approximately 2% of all tumours [@R01], with an incidence of 39,900 new cases per 100,000 people in 2012 and a male-female ratio of 8.8:0.8 (9:0.7 in Italy) [@R02]. It is considered the second most frequent neoplasia of the respiratory system after lung cancer.

Mortality estimated for LSCC was 19,800 cases per 100,000 in 2012 in Europe, with a male-female ratio of 4.3:0.3 (3.3:0.3 in Italy) [@R02].

Specific survival for larynx tumour is conditioned by many prognostic factors; the presence of cervical nodal metastasis represents the single most important prognostic factor [@R03] [@R04]. The 2-year overall survival of pN+s patients is reduced by 40-50% (88.01% in the pN0 vs. 41.54% in pN+) [@R04].

At present, there are no valid prognostic factors that can systematically drive the choice of nodal treatment in laryngeal carcinoma [@R05].

It is a consensus opinion in the literature that biomolecular markers can fill this deficiency [@R06] [@R09], especially considering the high potential of the studies on miRNAs.

miRNAs are small non-coding RNAs that regulate posttranscriptional gene expression through mechanisms of degradation of the messenger (only in vegetables and bugs) or simple sequestration with inhibition of translation (the mechanism present in humans) [@R10] [@R11].

An important feature of miRNAs is their ability to take part simultaneously in different pathways through the contemporary interaction with multiple messenger targets. Currently there are many studies that show the key role of miRNAs in the genesis, progression and metastatic ability of tumours [@R12] [@R14].

Different miRNAs are implicated in tumorigenesis by acting through oncogenes or through tumor-suppressor genes, therefore their expression in tumoural tissues, in comparison to healthy tissue, can reveal under- or overexpression [@R15].

The discovery that miRNAs are frequently deregulated in tumours offers the opportunity to identify them as prognostic and diagnostic markers.

The aim of this multicentric study wasn to identify a miRNA expression profile specific for laryngeal cancer. The secondary endpoint was to identify specific deregulated miRNAs with potential as prognostic biomarkers of tumour spread and nodal involvement, and specifically a miRNA pattern pathognomonic for N+ laryngeal cancer and for N- tissues.

Materials and methods {#S2}
=====================

Patient enrollment {#S2a}
------------------

This study included 24 patients suffering from laryngeal carcinoma, 22 males and 2 females, with an average age of 60 years (39-77). All the patients came from Campania and were treated for a laryngeal tumour at the Complex Operative Unit (COU) of Otorhinolaryngology of the University Hospital Policlinico \"Federico II\", at the COU of Otorhinolaryngology and Cervico-facial Surgery of the Hills Specialist Hospital Monaldi-Cotugno-CTO and at the COU of Otorhinolaryngology of the \"A. Cardarelli\" National Relief Hospital from January to June 2014. All patients underwent the following diagnostic procedures:

1.  Laryngeal endoscopy.

2.  Computerised tomography (CT) of the neck and chest with and without contrast.

3.  Multiple laryngeal biopsies with histological examination.

The TNM classification was applied in all cases according to the 2010 AJCC criteria.All patients were submitted to \"open\" laryngeal surgery and bilateral nodal cervical emptying. In all cases a sample of approximately 1 cm x 0.5 cm was withdrawn both from healthy tissue and macroscopically tumoral tissue from the removed larynx, which was immediately introduced into RNA later^®^ tubes. The same patients were submitted to blood draw, and serum was subsequently cryopreserved at -80°C.

The study was approved by the respective Ethics Committees.

Extraction of miRNAs {#S2b}
--------------------

The RNA was drawn out using the mirVana PARIS kit (Ambion) according to the protocol described by the supplier. A 0.5 mg sample of tumour tissue and the same quantity of healthy tissue were used. The concentration of the RNA was determined using a Nano Drop spectrophotometer by nanodrop reading.

Expression profile of miRNAs {#S2c}
----------------------------

The miRNA expression profile was determined using the TaqMan Array Card Type A (Life Technologies) according to the protocol Megaplex pool A. Experiments were performed on a thermocycler Viia7 (Life Technologies, Inc.), and the relative expression was computed by using the 2^--ΔΔCT^ formula and normalised using the endogenous U6. For the determination of miRNAs, we used standard cards that allow assessment of 382 different miRNAs of known function. The cards were provided by the manufacturer and used following the manufacturer\'s instructions (Life Technologies, Inc.).

Analysis of miRNA expression profile in laryngeal tumoural tissues {#S2d}
------------------------------------------------------------------

The RNA extracted from patients\' samples was assembled into two pools, the first including patients with stage T3 and T4 tumours and nodal involvement (N+) and the second comprising patients with stage T3 and T4 tumours without nodal involvement (N-). The control pool consisted of RNA extracted from healthy biopsy tissue taken from the same patients enrolled for pools N+ and N-.

Results {#S3}
=======

All patients were submitted to \"open\" surgery of the larynx (2 OSL, 3 CHEPs, 19 total laryngectomies).

In all patients, histological examination led to a diagnosis of squamous cell carcinoma. After histological examination, patients were classified according to both the TNM and histological grading as detailed in [Table I](#T1){ref-type="table"}.

###### 

p TNM, Grading and laryngectomy type of the 24 patients enrolled in the study.

  Number   pTNM   Grading   Laryngectomy type
  -------- ------ --------- -------------------
  1        T3N2   G3        Total
  2        T4N2   G2        Total
  3        T3N3   G2        Total
  4        T4N2   G3        Total
  5        T3N0   G2        Total
  6        T4N0   G2        Total
  7        T3N0   G2        Total
  8        T3N2   G3        Osl
  9        T3N0   G3        Chep
  10       T3N1   G3        Total
  11       T4N0   G3        Total
  12       T4N1   G2        Total
  13       T3N0   G3        Total
  14       T4N3   G3        Total
  15       T3N1   G4        Total
  16       T3N0   G3        Total
  17       T3N2   G2        Chep
  18       T3N2   G3        Osl
  19       T3N0   G2        Total
  20       T3N2   G2        Total
  21       T3N0   G3        Total
  22       T4N0   G3        Total
  23       T3N0   G2        Total
  24       T3N0   G2        Chep

The pTNM scores of the 24 treated patients and grading were as follow:

-   17 pT3, 7 pT4;

-   12 pN0, 3 pN1, 7 pN2, 2 pN3;

-   11 G2, 12 G3, 1 G4.

All patients included in the study of miRNA expression were selected with homogeneous characteristics regarding both T (pT3 and pT4) and grading. These 24 patients were then divided into two homogenous groups with respect to age, T stage and histological grade on the basis of lymph node involvement found in histological examination: 12 patients were pN+ and 12 patients pN-, respectively.

The characteristics of patients based upon the degree of T and presence of lymph node involvement in selected patients were:

-   9 patients pT3N0;

-   8 patients pT3N+;

-   3 patients pT4N0;

-   4 patients pT4N+.

The miRNAs extracted from the 24 selected patients were analysed, and the results of differential expression of miRNAs are described below and shown in [Tables II](#T2){ref-type="table"} to [VI](#T6){ref-type="table"}.

###### 

miRNAs overexpressed in tumour tissues in comparison with healthy tissues in patients with LSCC.

  miRNAs with fold change \>10   miRNAs with 5 \< fold change \< 10   miRNAs with 2 \< fold change \< 5
  ------------------------------ ------------------------------------ -----------------------------------
  hsa-miR-106b                   hsa-let-7d                           hsa-let-7a-
  hsa-miR-10b                    hsa-miR-101                          hsa-let-7e-
  hsa-miR-130b                   hsa-miR-103                          hsa-let-7 g-
  hsa-miR-15b                    hsa-miR-106a                         hsa-miR-10a-
  hsa-miR-185                    hsa-miR-135b                         hsa-miR-125b-
  hsa-miR-19a                    hsa-miR-141                          hsa-miR-127-
  hsa-miR-205                    hsa-miR-142-5p                       hsa-miR-130a-
  hsa-miR-20a                    hsa-miR-15a                          hsa-miR-132-
  hsa-miR-21                     hsa-miR-17                           hsa-miR-138
  hsa-miR-221                    hsa-miR-181a                         hsa-miR-148a
  hsa-miR-25                     hsa-miR-182                          hsa-miR-149
  hsa-miR-299-5p                 hsa-miR-193a-5p                      hsa-miR-152
  hsa-miR-455                    hsa-miR-19b                          hsa-miR-155
  hsa-miR-494                    hsa-miR-210                          hsa-miR-192
  hsa-miR-511                    hsa-miR-223                          hsa-miR-194
  hsa-miR-598                    hsa-miR-23b                          hsa-miR-199a-3p
  hsa-miR-708                    hsa-miR-27a                          hsa-miR-200a
  hsa-miR-9                      hsa-miR-27b                          hsa-miR-200b
                                 hsa-miR-340                          hsa-miR-203
                                 hsa-miR-34a                          hsa-miR-24
                                 hsa-miR-429                          hsa-miR-26b
                                 hsa-miR-532                          hsa-miR-28-3p
                                 hsa-miR-655                          hsa-miR-29a
                                 hsa-miR-660                          hsa-miR-29b
                                 hsa-miR-886-3p                       hsa-miR-29c
                                 hsa-miR-92a                          hsa-miR-301b
                                 hsa-miR-99b                          hsa-miR-30b
                                                                      hsa-miR-30c
                                                                      hsa-miR-32
                                                                      hsa-miR-324-5p
                                                                      hsa-miR-331
                                                                      hsa-miR-335
                                                                      hsa-miR-337-5p
                                                                      hsa-miR-374
                                                                      hsa-miR-422a
                                                                      hsa-miR-425-5p
                                                                      hsa-miR-454
                                                                      hsa-miR-483-5p
                                                                      hsa-miR-508
                                                                      hsa-miR-532-3p
                                                                      hsa-miR-590-5p
                                                                      hsa-miR-744
                                                                      hsa-miR-758
                                                                      hsa-miR-99a

###### 

miRNAs downregulated in tumor tissues in comparison with healthy tissues of patients with LSCC.

  miRNA            N- fold change   N+ fold change
  ---------------- ---------------- ----------------
  hsa-miR-1        0.072            0.040
  hsa-miR-126      0.528            0.592
  hsa-miR-133a     0.016            0.009
  hsa-miR-133b     0.118            0.046
  hsa-miR-139-5p   0.210            0.354
  hsa-miR-140-3p   0.378            0.333
  hsa-miR-186      0.857            0.497
  hsa-miR-204      0.514            0.507
  hsa-miR-375      0.175            0.742
  hsa-miR-449      0.125            0.013
  hsa-miR-449b     0.445            0.139
  hsa-miR-486      0.403            0.450
  hsa-miR-489      0.588            0.605
  hsa-miR-539      0.195            0.154
  hsa-miR-574-3p   0.705            0.385
  hsa-miR-628-5p   0.549            0.440
  hsa-miR-885-5p   0.222            0.130

###### 

Twelve miRNAs with different expression between the two groups of patients (N-, N+). miRNAs overexpressed are in red, miRNAs downregulated compared to healthy control tissue of patients with LSCC are in blue.

  miRNA            N- fold change   N+ fold change
  ---------------- ---------------- ----------------
  hsa-let-7b       1.391            2.437
  hsa-miR-135a     0.631            3.538
  hsa-miR-20b      1.467            3.981
  hsa-miR-212      0.147            0.756
  hsa-miR-324-3p   1.375            2.476
  hsa-miR-328      1.482            0.519
  hsa-miR-365      3.353            1.352
  hsa-miR-376a     1.338            0.586
  hsa-miR-493      1.986            0.539
  hsa-miR-500      2.771            1.297
  hsa-miR-642      0.452            1.375
  hsa-miR-886-5p   1.221            3.049

###### 

miRNAs expressed only in pathological tissue and not in control healthy tissue from the same patients.

  hsa-miR-181c     hsa-miR-509 5p
  ---------------- -----------------
  hsa-miR-183      hsa-miR-512 3p
  hsa-miR-18a      hsa-miR-517a
  hsa-miR-22       hsa-miR-517c
  hsa-miR-331 5p   hsa-miR-523
  hsa-miR-362 3p   hsa-miR-548c 5p
  hsa-miR-363      hsa-miR-570
  hsa-miR-424      hsa-miR-576 3p
  hsa-miR-455 3p   hsa-miR-579
  hsa-miR-502 3p   hsa-miR-583 3p

###### 

Twenty-three miRNAs expressed only in the N- group, 15 miRNAs expressed only in the N+ group. Red: overexpression with respect to healthy control tissue from the patients with LSCC; blue: downregulation with respect to healthy control tissues from the patients with LSCC; n.e.c.: no expression change.

  N-                Fold change   N+                Fold change
  ----------------- ------------- ----------------- -------------
  hsa-miR-146b-3p   1879          hsa-miR-190       0787
  hsa-miR-148b      2455          hsa-miR-486-3p    0047
  hsa-miR-338-3p    1043          hsa-miR-542-5p    2795
  hsa-miR-339-5p    0359          hsa-miR-618       13980
  hsa-miR-485-3p    2172          hsa-miR-198       n.e.c.
  hsa-miR-518b      0829          hsa-miR-342 5p    n.e.c.
  hsa-miR-518f      0509          hsa-miR-369 3p    n.e.c.
  hsa-miR-627       0827          hsa-miR-373       n.e.c.
  hsa-miR-216b      n.e.c.        hsa-miR-433       n.e.c.
  hsa-miR-296       n.e.c.        hsa-miR-450b 5p   n.e.c.
  hsa-miR-323 3p    n.e.c.        hsa-miR-487b      n.e.c.
  hsa-miR-372       n.e.c.        hsa-miR-545       n.e.c.
  hsa-miR-382       n.e.c.        hsa-miR-597       n.e.c.
  hsa-miR-503       n.e.c.        hsa-miR-876 3p    n.e.c.
  hsa-miR-518c      n.e.c.        hsa-miR-876 5p    n.e.c.
  hsa-miR-529a      n.e.c.                          
  hsa-miR-522       n.e.c.                          
  hsa-miR-548d      n.e.c.                          
  hsa-miR-582 5p    n.e.c.                          
  hsa-miR-636       n.e.c.                          
  hsa-miR-651       n.e.c.                          
  hsa-miR-873       n.e.c.                          
  hsa-miR-137       n.e.c.                          

Expression analysis showed that normal tissues expressed 180/382 miRNAs, the N- pool expressed 207/382 miRNAs and the N+ pool expressed 200/382 miRNAs.

Comparative analysis between the N+ and N- pools and the control pool showed that in both groups of patients, 89 miRNAs were overexpressed compared to normal tissue counterparts, and are collected in three groups in [Table II](#T2){ref-type="table"} on the basis of their relative expression; 17 miRNA were downregulated, and are shown in [Table III](#T3){ref-type="table"}.

Analyzing the N+ and N- pools separately and comparing them to healthy control tissues from the same patient, it is evident that 12 miRNAs were differentially expressed in the two groups of patients and compared to healthy control tissue ([Table IV](#T4){ref-type="table"}). In particular, 4 miRNAs were overexpressed in N+ patients with respect to both the N- and healthy tissues, 3 miRNAs were downregulated in N+ patients compared to both the N- and healthy tissues, 2 were overexpressed in N- patients with respect to both the N+ and healthy tissues, 2 miRNAs were downregulated in N- patients compared to both N+ and healthy tissues, 1 was overexpressed in N+ patients compared to healthy tissues and downregulated in Npatients compared to the healthy tissue of 24 selected patients with LSCC.

Twenty miRNAs were expressed only in the two groups of patients (N+ and N-) and not in healthy control tissues from the same patients ([Table V](#T5){ref-type="table"}). Therefore, these miRNAs are expressed only in tumour tissues.

Fifteen miRNAs were expressed only in the N+ group, and 23 miRNAs were expressed only in the N- group ([Table VI](#T6){ref-type="table"}).

Discussion {#S4}
==========

Laryngeal tumours identical in site, subsite and clinical stage, and subjected to the same treatment may have different clinical outcomes and prognosis, especially when considering nodal spreading.

In this study, we analysed the expression of miRNAs in tissues resulting from carcinomas of the larynx to identify a tissue-specific miRNA signature predictive of unfavourable development toward lymph node metastases.

Even if the population under study is very limited in number, the results are of considerable interest. The comparative data show that the miRNA expression profiles in pathological tissues compared to healthy tissues exhibit a clear majority of overexpressed miRNAs with only a few hypoexpressed miRNAs.

Some of the miRNAs overexpressed in the diseased tissues have already been described in the literature, also in relation to cancer of the larynx:

-   **miR19a:** Marioni et al., recently, have demonstrated its higher expression in malignant glottis lesions than in benign conditions [@R16]. It was previously correlated with neck nodal metastasis, poor differentiation and advanced stage when overexpressed [@R17].

-   **miR 27a:** it has been shown that miR27a promotes proliferation and suppresses apoptosis [@R18] [@R19].

-   **miR 155:** the expression of tissue and plasma miR155 is significantly upregulated in patients with LSCC [@R20]; furthermore, it seems to play a role in development of LSCC in terms of promotion of proliferation and invasion [@R21].

-   **miR 21:** some authors have described its overexpression in laryngeal cancer tissues [@R22] [@R23], and its ratio with miR375 (miR21/miR375) has been related with worse prognosis if high [@R24] [@R25]; and its high expression in serum is associated with nodal metastasis in LSCC [@R26]. Recently, miR21 was shown to be deregulated by acidic bile and implicated in precancerous lesiosn of laryngeal mucosa [@R27].

-   **miR 106b:** it was found to be upregulated in LSCC tissues, together with miR21, and their level were found to be increased in poorly/moderately differentiated (G2-G3) cancer tissues and associated with lymph node metastasis [@R28].

-   **miR 375:** according to Wu et al., increased expression of miR375 is associated with a more aggressive phenotype of LSCC; moreover, a high-level expression of miR375 and miR148a in patients with laryngeal dysplasia may predict malignant transformation [@R29]. In our study, it was downregulated in tumour tissues in agreement with Hu [@R25].

-   **miR 708:** it is upregulated in tumour tissues as is miR21 and miR205 [@R30] according to our data.

-   **miR 205:** it is upregulated in tumour tissues (as in our study), and in addition it significantly induces cell proliferation and invasion by suppressing CDK2AP1 [@R31].

-   **miR 221:** Yilmaz demonstrated that it is upregulated in LSCC plasma samples, but was at normal levels in postoperative plasma; he proposed it as a diagnostic marker of LSCC [@R32].

Among the overexpressed miRNAs (fold change between 2 and 5) in tumour tissues, some have described to be down-regulated in patients with LSCC.

-   **miR 203:** according to Tian et al., its lower expression is related to poor differentiation, advanced clinical stage, lymph node involvement and decreased 5-year overall survival [@R33]. Recently, it has been shown to correlate with local disease recurrence after radiotherapy in a series of patients with laryngeal cancer [@R34].

-   **miR 152:** it was described as significantly downregulated in supraglottic laryngeal carcinoma tissues and its expression was correlated with p T and p N stages in patients with supraglottic LSCC [@R35].

-   **miR 24:** its upregulation, similar to miR27a, leads to promotion of proliferation and early apoptosis inhibition in LSCC [@R18]; according to Xu et al., miR24 expression is significantly lower in LSCC cell lines and it inhibits growth-related apoptosis and enhances radiosensitivity in LSCC [@R36].

Of considerable interest are miRNAs detected in our study and not yet associated with cancer of the larynx, even though they have been previously associated with other tumours. This is the case of six miRNAs: **mir9** [@R37], **mir511** [@R38], **mir494** [@R39], **mir25** [@R40], **mir20** [@R41], and **mir10b** [@R42], which are greatly overexpressed in several tumour tissues compared to healthy control tissues from the same patients.

Interestingly, we identified some miRNAs with specific expression in either N+ or N- cases.

The analysis of the N+ group detected the following miRNAs:

-   **miR618:** strongly overexpressed in our study in N+ patients; it is considered by Hui to be a prognostic factor for HNSCC (head and neck squamous cell carcinoma) [@R43]. It has been also correlated with thyroid cancer [@R44].

-   **miR 542-5p:** overexpressed in tumour tissues in our series of N+ patients, it was previously reported in rhabdomyosarcoma [@R45] and osteosarcoma [@R46].

-   **miR 486-3p:** downregulated in tumour tissues of patients with nodal metastases compared to healthy control tissues from the same patients, its decreased level has been associated with metastasis in cervical cancer patients [@R47].

-   **miR 135 a:** on the basis of our data, this miRNA is overexpressed in tumour tissues of N+ patients compared to healthy control tissues and downregulated in tumour tissues of patients without lymph node involvement compared to healthy tissue from the same patients. Its high expression in gastric cancer tissues is more likely to have aggressive characteristics, among which lymphatic metastasis [@R48].

-   **miR 20b:** overexpressed in tumour tissues of N+ patients, it was associated with laryngeal cancer in 2010 [@R49]; its upregulation promotes proliferation, migration and invasiveness in oesophageal tumours [@R50].

-   **miR 324-3p:** overexpressed in tumour tissues of N+ patients, it is upregulated in plasma of stage I of lung squamous cell carcinoma compared to healthy controls [@R51]; furthermore, its low expression might be an important marker for prediction of low response to RT/CRT and poor overall survival and recurrence-free survival [@R52].

Analyzing the 12 N- patients, the most interesting miRNAs for their biological functions are the following:

-   **miR 148b:** overexpressed in the diseased tissue of pNpatients, it has been linked with melanoma [@R53].

-   **miR 339-5p:** downregulated in tumour tissues of pNpatients, it has been described as a regulator of breast cancer progression [@R54].

-   **miR 485-3p:** overexpressed in the diseased tissue of patients without lymph node metastasis, it is described as a suppressor of breast cancer metastasis [@R55].

-   **miR 518f:** downregulated in tumour tissues of pN- patients compared to control tissue, it is related to endometrial cancer in which it is downregulated [@R56].

Through analysis of these results, we may define a tissuespecific miRNA signature that is predictive of lymph node metastases in laryngeal carcinoma characterised by 11 miRNAs, seven of which are overexpressed (upregulated) and four downregulated, in particular: miR618, miR542- 5p, let 7b, miR135a, miR20b, miR324-3p, and miR886- 5p are overexpressed; and miR486-3p, miR328, miR376a and miR493 are downreguated. This signature is suggestive to be predictive of lymph node involvement even if the validation of these results on a wider series of patients is strongly warranted.

Conclusions {#S5}
===========

We have identified a group of miRNAs with characteristic expression profiles in diseased tissues compared to matched healthy tissue from the same patients; in addition, we have highlighted a miRNA pattern specific of N+ laryngeal cancer cases compared to N- cases and healthy tissues. Furthermore, the authors have detected a miRNA pattern expressed specifically in laryngeal cancer tissues (and not in healthy tissues), one expressed exclusively in laryngeal cancer with N+ and another one present in N-. These results are largely innovative, at least in our opinion, and allow the identification of a group of potentially specific tumour biomarkers for laryngeal carcinoma that can be used to improve its diagnosis, particularly at early stages, and to detect patients with minimal residual disease or recurrence if the miRNA pattern specific of laryngeal cancer is present; but, overall, they can be useful to predict prognosis atient in early stages on the basis of the identification of the miRNAs signature suggestive for nodal involvement. In this case, the miRNAs could lead to tailored treatment.

The technologies of molecular biology are not yet available in all centres, so that the use of miRNA profiling with microarray techniques on large scale in diagnosis of laryngeal carcinoma is not readily possible. However, the methods of real-time PCR are presently relatively cheap and easy to perform. The bottleneck in this type of study is, in fact, the identification of differentially expressed miRNAs through the use of low-density arrays (as in our case) and their subsequent validation in a large population of patients. Once validated, the miRNA biomarkers are easy to detect in the tissue of patients with cancer and other neoplasms. Another advantage of miRNAs is their presence in all body fluids, and in particular in plasma and serum of patients, in which they can be easily detected and quantified [@R57]. A further phase of the present study is, in fact, the determination of an array of circulating miRNA in serum from the same patients, which will be determined and cross-referenced with those obtained in tissues of the same patients. In this way, we can outline a limited group of very reliable miRNAs that can be validated (or not) together with a \"portfolio of prognostic factors\" (clinical and pathological) for routine use in clinical evaluation.
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